Clinuvel Investors' Area

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders.

With our unique expertise in understanding the interaction of light and human skin, the company has identified three groups of patients with a clinical need for photoprotection and another group with a need for repigmentation. These patient groups range in size from 10,000 to 45 million.

Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and been granted marketing authorisation for EPP by the European Medicines Agency (EMA) for the prevention of phototoxicity in adult EPP patients. Based in Melbourne, Australia, Clinuvel has operations in Europe and the US.

Share Price

Buy : 4.8

Sell : 4.9

First : 4.82

Last : 4.8

High : 4.86

Low : 4.8

ASX: CUV 20 mins delay.

Volume : 18,139 Trades: 13

Last Traded : 24-May-2016 14:42:53

Clinuvel on Twitter

Clinuvel Stock Ticker

Quick Links